April 20th 2024
Patients with locally advanced or metastatic urothelial cancer treated with enfortumab vedotin plus pembrolizumab experienced a reduction in the risk for disease progression or death vs chemotherapy.
The Latest on Acute Lymphocytic Leukemia
View More
A Focus on Acute Myeloid Leukemia
View More
Updates in Myelodysplastic Syndromes
View More
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
Advances In™: Targeting PSMA to Advance Diagnosis And Management Of Patients With Prostate Cancer
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
8th Annual School of Nursing Oncology™
August 10, 2024
Register Now!
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Prostate Cancer Foundation Partners with Movember Foundation
October 28th 2014The Prostate Cancer Foundation (PCF) announced that the partnership with the Movember Foundation has resulted in 7 new Challenge Awards for 2014. In May, it was announced that PCF received over $8.4 million from the Movember Foundation, the leading global organization committed to changing the face of men's health.
Fall Patient Insight Webinars from the Bladder Cancer Advocacy Network
October 20th 2014The Bladder Cancer Advocacy Network has announced its fall series of webinars, featuring bladder cancer experts on a variety of topics. The webinars are relevant to people with bladder cancer, caregivers, family, and friends:
For Men With Prostate Cancer, Vessel-Sparing Radiation Can Preserve Sexual Function
September 17th 2014With the use of MRI imaging to restrict doses to erectile tissues, nearly half of men treated with external beam radiation therapy (EBRT) for prostate cancer were able to be sexually active without aids or medications 5 years later, and nearly 80% could be sexually active if such support was an option
No Matter Who You Are, Get Checked!
July 23rd 2014It happens all the time. A man gets older, but he doesn't think he needs to be checked for prostate cancer. Even if his father or grandfather had prostate cancer, he feels fine, and does not see the need for yearly physical exams. However, the reality is that 1 in 7 American men will be diagnosed with prostate cancer at some point in his lifetime.
Pamela Devine Discusses Psychosocial Issues Concerning Men with Prostate Cancer
July 16th 2014Pamela Devine, RN, clinical nurse specialist, Philadelphia Veterans Administration Medical Center, discusses some of the psychosocial issues that men face when they are receiving treatment for their prostate cancer.
Managing Side Effects of Androgen-Deprivation Therapy Increasingly Important
July 9th 2014Androgen-deprivation therapy (ADT) is a mainstay of treatment for prostate cancer in a number of settings, so managing its side effects is becoming increasingly important for urologists and oncology practitioners in collaboration with primary care physicians.
Follow-up Confirms Safety of Radium-223 in mCRPC
April 1st 2014Extended follow-up of patients with castration-resistant prostate cancer (CRPC) and bone metastases randomized to radium-223 dichloride in the phase III ALSYMPCA study revealed a continued low incidence of myelosuppression and no association with secondary malignancies.
Donna L. Berry on Decision Support for Men With Prostate Cancer
February 6th 2014Donna L. Berry, PhD, RN, AOCN, FAAN, Director, Phyllis F. Cantor Center for Research in Nursing & Patient Care Services, Dana-Farber Cancer Institute, Associate Professor, Department of Medicine, Harvard Medical School, discusses decision support for men with localized prostate cancer.